Hypothalamic Obesity
20
4
5
10
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 20 trials
100.0%
+13.5% vs benchmark
30%
6 trials in Phase 3/4
50%
5 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (20)
A Trial of Setmelanotide in Acquired Hypothalamic Obesity
Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity
A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
Tirzepatide in PWS, HO and GNSO
Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity
Open-Label Study of Setmelanotide in Hypothalamic Obesity
Identification and Clinical Relevance of an Oxytocin Deficient State (Melatonin Study)
The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study
Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)
Intranasal Oxytocin in Hypothalamic Obesity
Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity
Neuromodulation for Hypothalamic Obesity
Effects of Exenatide on Hypothalamic Obesity
A Personalized Program of Physical Activity and Diet for Hypothalamic Obesity
Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide Therapy
Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage
A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients